ကူးယူချက် 🔗
WEBVTT
00:00:06.400 --> 00:00:10.960
Here are three numbers to sit with even before we say hello.
00:00:11.839 --> 00:00:13.759
71.2%.
00:00:15.119 --> 00:00:27.359
Now this is the proportion of patients with moderate to severe PTSD who, after just three sessions of MDMA assisted therapy, no longer met criteria for PTSD at all.
00:00:27.760 --> 00:00:30.239
This was published in Nature Medicine.
00:00:30.879 --> 00:00:32.479
Here's another number.
00:00:33.119 --> 00:00:35.200
29.1%.
00:00:36.560 --> 00:00:48.240
This is the remission rate, full remission, not just response in patients with TRD treatment-resistant depression, three weeks after a single 25 milligram dose of psilocybin.
00:00:48.719 --> 00:00:52.079
Now this was published in the New England Journal of Medicine.
00:00:52.799 --> 00:00:54.000
And 83%.
00:00:55.679 --> 00:01:05.280
That is the reduction in heavy drinking days among people with alcohol use disorder who received psilocybin-assisted psychotherapy.
00:01:05.439 --> 00:01:08.640
Now this was published in JAMA Psychiatry.
00:01:09.920 --> 00:01:21.519
Folks, these are real numbers from peer-reviewed randomized controlled trials, and today I'm going to walk you through the full neurobiological and clinical story behind them.
00:01:22.319 --> 00:01:35.200
Because if we're going to make the case that psychedelics belong inside the tent of positive psychiatry, that case has to be built on data, not just on enthusiasm.
00:01:36.159 --> 00:01:41.200
Welcome, my dear friends, to positive psychiatry with Rakesh Jan Podcast.
00:01:41.439 --> 00:01:44.000
I'm your host, Rakesh.
00:01:44.319 --> 00:01:49.120
And today's question: positive psychiatry and psychedelics.
00:01:49.439 --> 00:01:52.239
Are they a marriage made in heaven?
00:01:52.480 --> 00:01:58.159
And I'll add this, or just an overhyped, rebound relationship.
00:01:58.560 --> 00:02:21.919
Over the next few minutes, we're going to move from the intracellular geography of a single serotonin receptor all the way out to clinical remission rates, flourishing scale effect sizes, and the reality of what stands in front of the field as far as barriers go in 26 and 27.
00:02:22.800 --> 00:02:23.840
Let's do this.
00:02:24.000 --> 00:02:26.479
Let's go on this journey.
00:02:28.159 --> 00:02:32.879
So, how can we even begin this journey without tackling this question?
00:02:33.199 --> 00:02:36.080
What positive psychiatry actually is?
00:02:36.479 --> 00:02:52.639
So before we talk about psilocybin and MDMA and LSD and ayahuasca and methylome and all that stuff, we need to agree on what positive psychiatry actually is, because the term does get used quite loosely.
00:02:53.360 --> 00:02:58.800
Sometimes it's nothing but a synonym for optimism or a wellness culture.
00:02:59.120 --> 00:03:00.800
It is neither of those things.
00:03:00.879 --> 00:03:04.639
It's in fact a measurement-based clinical discipline.
00:03:04.960 --> 00:03:08.400
Positive psychiatry was formally defined by
Load full transcript
Dr.
00:03:08.560 --> 00:03:15.120
Dilip Jeste and Barton Palmer, both of them from University of California, San Diego.
00:03:15.759 --> 00:03:23.120
And they did this in their 2015 handbook and a series of papers they published in the Journal of Clinical Psychiatry.
00:03:23.199 --> 00:03:37.520
And I would quote, the science and practice of psychiatry that focuses on the study and promotion of mental health and well-being through enhancement of positive psychosocial factors.
00:03:37.840 --> 00:03:38.960
End of quote.
00:03:39.439 --> 00:03:42.000
Notice what the definition does not say.
00:03:42.240 --> 00:03:49.039
It does not say that positive psychiatry can only happen in the absence of psychopathology.
00:03:49.439 --> 00:03:50.159
In fact, Dr.
00:03:50.319 --> 00:03:58.639
Jeste's own framing is that roughly 20% of people are affected by a diagnosable mental condition at any one point.
00:03:59.360 --> 00:04:03.199
But 100% of people have mental health, right?
00:04:03.599 --> 00:04:11.199
In the sense of having a level of well-being, resilience, psychosocial factors that can be measured, targeted, and improved.
00:04:11.439 --> 00:04:14.960
Whether they have a DSM diagnosis or not.
00:04:15.199 --> 00:04:23.120
But the truth is, this is particularly problematic, mental well-being in those with a psychiatric illness.
00:04:23.759 --> 00:04:27.439
So Just is model names four core components.
00:04:27.519 --> 00:04:34.959
And I want to give you all four because we're going to circle back to each one when we get to the psychedelic data.
00:04:35.199 --> 00:04:43.439
The first is positive mental health outcomes, well-being, life satisfaction, quality of life.
00:04:43.759 --> 00:04:58.240
Second, positive psychosocial characteristics, such as resilience and optimism, and coping and self-efficacy and social engagement and spirituality and, of course, wisdom.
00:04:59.199 --> 00:05:04.639
The third is measurement-based tools to actually quantify these characteristics.
00:05:04.879 --> 00:05:13.439
Because as every one of us in clinical practice knows, what doesn't get measured doesn't get systematically treated.
00:05:13.680 --> 00:05:18.639
And we don't manage hypertension by asking patients how their blood pressure feels.
00:05:19.199 --> 00:05:27.040
And in some ways, positive psychiatry insists that we should manage well-being by actually using measurement-based care.
00:05:27.680 --> 00:05:50.480
And then finally, the fourth pillar: interventions can be developed specifically designed to enhance these characteristics, not just to reduce the PHQ-9 or a madras score, that would of course be great, but in order to build gratitude, connectedness, and meaning as primary therapeutic targets in their own right.
00:05:51.439 --> 00:05:56.160
Now, folks, there is a companion framework you probably encountered by Dr.
00:05:56.319 --> 00:05:57.920
Martin Sligman.
00:05:58.480 --> 00:06:05.439
He is from University of Pennsylvania, and he created a model that I personally have been very influenced by.
00:06:05.680 --> 00:06:09.199
It's called the PERMA model, P-E-R-M-A.
00:06:09.759 --> 00:06:11.199
What does that stand for?
00:06:11.920 --> 00:06:22.720
Positive emotion, engagement, relationships, meaning, and accomplishment.
00:06:23.519 --> 00:06:30.399
Jeste explicitly incorporates PERMA into positive psychiatry's conceptual architecture.
00:06:30.720 --> 00:06:44.079
And you will hear several of these exact five letters reappear as outcome variables later in this episode of ours when we examine positive psychiatry and psychedelics.
00:06:44.319 --> 00:06:48.879
So these would be things like connectedness, meaning, positive affect.
00:06:49.360 --> 00:06:53.360
Those are things we'll be talking about in just a little bit.
00:06:54.000 --> 00:07:10.000
And here's why this framing matters for today's discussion, because traditional psychopharmacology, and folks, I say this not as a critic of it, but as a card-carrying member of it, is indeed largely symptom subtraction medicine.
00:07:10.560 --> 00:07:22.399
We measure a madras or a CAP score or a GAD-7 or a PHQ 9, and then we give a medication or a psychotherapy, and we watch the number go down over weeks.
00:07:22.560 --> 00:07:24.079
That's enormously valuable.
00:07:24.160 --> 00:07:25.600
And I'm not here to diminish it.
00:07:25.680 --> 00:07:26.879
Oh God no.
00:07:27.519 --> 00:07:44.079
It is also by itself, however, an incomplete model of mental health because a person can have a madras score of eight, technically, not depressed, and still have no sense of meaning or connectedness or growth.
00:07:44.480 --> 00:07:47.040
Nothing resembling flourishing.
00:07:47.360 --> 00:07:48.079
Go ahead.
00:07:48.240 --> 00:07:50.160
Let's kind of work on this together.
00:07:50.399 --> 00:07:51.839
How is that remission?
00:07:52.879 --> 00:07:54.240
It's not, is it?
00:07:54.399 --> 00:08:03.759
It's remission if you define it poorly, but it's not remission if you really talk to the people who are afflicted with these conditions.
00:08:04.480 --> 00:08:07.680
So our question in this episode is this, isn't it?
00:08:07.759 --> 00:08:08.240
Quite simply.
00:08:08.399 --> 00:08:24.399
Do psychedelics, psilocybin, MDMA, LSD, and a whole host of other medications in development, do they do something categorically different than a standard SSRI or SNRI or anything like that?
00:08:24.720 --> 00:08:37.919
Do they move the positive psychiatry dials, meaning, connectedness, openness, pro-social behavior, gratitude, and not just a symptom reduction dial?
00:08:38.320 --> 00:08:53.600
As we'll discuss shortly, because the data suggests, I would say, and you of course will be the final judge if you're persuaded or not, that if one applies some nuance and applies some caveats, then the answer actually is yes.
00:08:53.919 --> 00:09:07.679
And then neurobiology gives us an increasingly plausible mechanism why there might actually be a marriage between
psychedelics and positive psychiatry.
00:09:09.120 --> 00:09:13.600
Let's start where any good psychopharmacology story should start.
00:09:13.919 --> 00:09:16.000
That is a receptor.
00:09:16.480 --> 00:09:27.600
So classic serotonergic psychedelics, I would say psilocybin, it's active metabolites, silocin, LSD, DMT, FIMEODMT.
00:09:27.679 --> 00:09:33.200
These are all agonists of the serotonin 5-HT2A receptor.
00:09:33.440 --> 00:09:53.600
Now, this receptor, folks, is densely deeply expressed in layer 5 of the pyramidal neurons throughout the cortex, particularly what one calls the neocortex, the neo part of the cortex that we humans have developed to a large degree.
00:09:53.759 --> 00:09:56.080
So we call that the prefrontal cortex.
00:09:56.159 --> 00:10:03.919
And 5-HD2 activation is necessary for essentially every downstream effect we're about to discuss.
00:10:04.080 --> 00:10:09.360
You block that receptor with an antagonist, it's often catanserin.
00:10:09.519 --> 00:10:17.600
And both the subjective psychedelic effects and the therapeutic effects in animal models, actually in human models too, disappears.
00:10:18.320 --> 00:10:23.200
But here's where the story gets genuinely interesting and pretty recent.
00:10:23.440 --> 00:10:29.039
So here's a paper from David Olson's laboratory from 2023.
00:10:29.120 --> 00:10:35.120
And folks get to know this name, David Olson, a major researcher.
00:10:35.440 --> 00:10:38.159
He asked a deceptively simple question.
00:10:38.320 --> 00:10:43.600
Now, serotonin itself binds 5HD2A receptors all day long, every day.
00:10:44.000 --> 00:10:53.120
Why doesn't this ambient serotonin produce the same plasticity-promoting effects as a single dose of a psychedelic?
00:10:53.919 --> 00:10:59.840
Well, the answer they found is about receptor location and not just receptor identity.
00:11:00.399 --> 00:11:09.759
They use some very fancy techniques to selectively deliver drugs to the inside versus the outside of the neurons.
00:11:09.919 --> 00:11:11.279
Can you believe that?
00:11:11.600 --> 00:11:12.799
They did that.
00:11:12.960 --> 00:11:23.519
And receptors sitting inside the cell, not on the surface, that's what drives the dendritogenesis, the growth of the new dendritic branches.
00:11:23.759 --> 00:11:35.039
So serotonin is relatively membrane impermeable and mostly cannot reach these intracellular receptors under normal physiologic conditions.
00:11:35.200 --> 00:11:40.000
Did you know we actually have receptors, serotonin receptors, inside the cell?
00:11:40.320 --> 00:11:47.919
Most likely we have not talked much about it because our treatments up to date have only worked on the cell surface.
00:11:48.159 --> 00:11:53.679
But psychedelics, because they are lipophilic, cross the membrane freely.
00:11:54.480 --> 00:12:08.639
And that single structural difference may explain why a molecule structurally similar to serotonin can produce the plasticity that serotonin itself at physiological concentrations does not.
00:12:09.120 --> 00:12:10.080
So thank you, Dr.
00:12:10.240 --> 00:12:18.480
Olson, because you have provided us an elegant answer to a question that has puzzled the field for years.
00:12:19.759 --> 00:12:21.679
Now what happens downstream, folks?
00:12:21.840 --> 00:12:29.440
Downstream of receptor activation, psychedelis engage the BDNF, Trek B signaling pathway.
00:12:29.600 --> 00:12:31.600
Please get to know that too, okay?
00:12:31.840 --> 00:12:39.759
Brain-derived neurotrophic factor and its receptor, tropomyosin receptor kinase B.
00:12:40.000 --> 00:12:42.879
Tropomyosin receptor kinase B.
00:12:42.960 --> 00:12:48.240
That's why we call it BDNF-TRK capital B.
00:12:48.639 --> 00:12:54.799
This is the same pathway implicated in the rapid antidepressant effects of ketamine.
00:12:55.440 --> 00:13:12.000
And there's a recent paper from 2026 using a neural stem cell-derived model shows that TREC B silencing, in fact, gets rid of the benefits of a psychedelic like dendritic building response.
00:13:12.480 --> 00:13:13.120
Wow.
00:13:13.600 --> 00:13:21.759
This points to a convergent final common pathway across two very different classes of rapid-acting antidepressants.
00:13:21.840 --> 00:13:25.200
One is glutamatergic and one is serotonergic.
00:13:25.759 --> 00:13:29.039
Now, what does this pathway actually build?
00:13:29.519 --> 00:13:44.960
Well, in models, animal models of cultured cortical neurons, a single application of a psychedelic compound produces measurable increases in dendritic spine density and its synaptogenesis.
00:13:45.679 --> 00:13:50.399
Increased dendritic spine density and synaptogenesis.
00:13:50.480 --> 00:13:52.000
So new synapses form.
00:13:52.399 --> 00:13:56.159
You can actually visualize them under a microscope.
00:13:56.480 --> 00:14:07.200
And this is a pretty big deal because this happens pretty quickly within 24 hours of treatment, alongside roughly a doubling of BDNF protein expression.
00:14:07.440 --> 00:14:09.679
This is pretty impressive.
00:14:10.080 --> 00:14:23.039
This matters, in fact, clinically, because decreased dendritic spine density in the front part of the brain, the prefrontal cortex, is a consistent finding in chronic stress models.
00:14:23.440 --> 00:14:32.879
And actually, even in humans, when postmortem tissue from people is captured if they suffered from major depression before they died.
00:14:33.360 --> 00:14:48.720
So if chronic stress and depression architecturally prune the cortex and psychedelics architecturally rebuild it, you can see, right, that we have a mechanistic hypothesis that maps directly onto clinical outcomes.
00:14:50.480 --> 00:14:57.600
Now, it's really important that I be a responsible podcast host to you and not just a cheerleader.
00:14:57.840 --> 00:15:01.840
Because the field is not without actually some internal disagreement.
00:15:01.919 --> 00:15:09.759
And a scientifically honest podcast like this one that I'm hoping that
it be has to show us the other side too, right?
00:15:10.639 --> 00:15:13.519
This is not always so.
00:15:13.840 --> 00:15:20.879
And there are many teams who have not been able to replicate the magnitude of psychedelic-induced neuroplasticity.
00:15:21.279 --> 00:15:30.799
There are more than one study that show that for some reason certain clinics, certain research centers are not able to replicate that.
00:15:31.039 --> 00:15:35.440
Now, none of this is to undercut the story because there's always outliers.
00:15:35.679 --> 00:15:45.200
But I thought it's important because ours is a scientific narrative that when there are disagreements amongst major researchers, we talk about it.
00:15:45.440 --> 00:15:48.799
But overall, it does seem that the field agrees.
00:15:49.039 --> 00:15:54.799
One needs these cellular changes before a person is better.
00:15:56.080 --> 00:15:59.120
Why don't we move from the synapse to the whole brain?
00:15:59.279 --> 00:16:07.600
Because this is where positive psychiatric constructs and psychedelic neurobiology converge most elegantly.
00:16:09.519 --> 00:16:20.080
Now, what we need to do is look at a paper by Joshua Siegel and colleagues just a couple of years ago, and they use precision functional mapping.
00:16:20.320 --> 00:16:32.799
That pretty much means they repeat very dense repeats of fMRI scanning in the same individual before and during and after a high dose of psilocybin.
00:16:33.440 --> 00:16:49.360
And what they found is psilocybin produces more than three times greater change in whole brain functional connectivity than a control medication they used, which was a stimulant, methylphenidate.
00:16:50.000 --> 00:17:05.599
So the dominant pattern of this connectivity, weirdly, is desynchronization, a temporary dissolution of the boundaries between large-scale brain networks, most prominently the default mode.
00:17:06.160 --> 00:17:10.319
Now here's the part that connects directly to positive psychiatry.
00:17:10.559 --> 00:17:19.839
The default mode network, widely known as DMN, is the network most active when we are engaged in self-referential thought.
00:17:20.000 --> 00:17:29.359
That means we're thinking about us, our life, we're ruminating, it's autobiographical memory, mental time travel.
00:17:29.680 --> 00:17:31.839
It's kind of the narrative sense of me.
00:17:32.000 --> 00:17:33.039
It's not selfish.
00:17:33.200 --> 00:17:35.599
It's more a narrative sense of me.
00:17:36.240 --> 00:17:49.039
In depression, PTSD, anxiety, this default mode network connectivity is overly stable, meaning folks are locked into this rigid self-critical loops of thought.
00:17:49.200 --> 00:17:50.640
They can't break it.
00:17:50.960 --> 00:18:20.880
And Robin Carhartt Harris and colleagues, and he was at Imperial College in London at that time, he proposed the entropic brain hypothesis, the idea that psychedelics actually increased the entropy or flexibility of the brain network dynamics, kind of loosening the
rigid patterns of thought and allowing new configurations, new perspectives, and new stories, new narratives to emerge.
00:18:21.119 --> 00:18:25.359
And once those narratives emerge, the person starts believing it.
00:18:25.839 --> 00:18:39.200
And in the same paper from Siegel and colleagues, the reduction in connectivity between the anterior hippocampus and the default mode network was not just an acute six-hour phenomena.
00:18:39.440 --> 00:18:43.200
It actually lasted for weeks after a single dose.
00:18:43.599 --> 00:18:52.960
That's right, even though the treatment was on one day and the medication effects essentially wore off after six to eight hours.
00:18:53.279 --> 00:18:57.359
These effects I just mentioned last for weeks.
00:18:58.240 --> 00:19:09.039
And these authors explicitly describe this as a neuroanatomical correlate that they called, very cool name, proplasticity.
00:19:09.359 --> 00:19:10.720
Proplasticity.
00:19:10.960 --> 00:19:30.720
And they believe that the durable therapeutic effects of psychedelics, which happens because of a window of heightened plasticity that outlasts the drug itself, is in fact almost like early childhood brain development relived and rewiring occurs.
00:19:31.279 --> 00:19:39.039
Kind of cool because this is precisely the neurobiological terrain where positive psychiatric constructs live.
00:19:39.359 --> 00:19:53.680
So meaning making, cognitive flexibility, the capacity to revise a rigid self-narrative, openness to experience, these are not vague humanistic concepts floating free of biology.
00:19:53.920 --> 00:20:09.759
They in fact appear to be functionally and structurally connected in exactly the same ways that networks are and that psychedelics transiently destabilize and allow for a reconsolidation.
00:20:09.920 --> 00:20:23.680
But hopefully the reconsolidation is in a healthier configuration, especially when the destabilization happens inside a supportive therapeutic framework with trained facilitators.
00:20:23.920 --> 00:20:29.839
Before we leave neurobiology, we should draw a quick contrast that I think sharpens the picture.
00:20:30.079 --> 00:20:51.119
Now, ketamine and its enantomer sketamine, which by the way is approved by the FDA for treatment resistant depression and also for the treatment of depression when suicidality is present, work primarily through the NMDA receptor and not the 5HD2A agonism approach.
00:20:51.359 --> 00:20:52.240
But you know what?
00:20:52.400 --> 00:21:02.400
They both converge on the same downstream BDNF-trek B, mTOR-dependent synaptogenesis pathway.
00:21:02.559 --> 00:21:07.440
So two very different routes, but they come to the same place.
00:21:08.000 --> 00:21:21.839
Now this is the convergence, is why researchers think it's a big part of why we should be thinking of them as rapid acting antidepressants, also known as RADS RAADS.
00:21:23.119 --> 00:21:35.839
So the target receptor may be 5HD2A or NMDA, but if you get to the ultimate common pathway, the benefits are obvious.
00:21:36.960 --> 00:21:42.000
Now we should turn our attention to another section of our conversation.
00:21:42.079 --> 00:21:47.519
And now we put that neurobiology to work and walk through the clinical evidence.
00:21:47.599 --> 00:21:54.000
And we start with major depression because that's where the largest, most rigorous trial program exists.
00:21:54.559 --> 00:21:59.839
So the foundational trial is a 2022 New England Journal of Medicine paper from Compensation.
00:22:00.240 --> 00:22:00.960
Pathway.
00:22:02.720 --> 00:22:11.519
Excuse me, this is a phase two double-blind randomized study of a lot of people, 233 participants with treatment-resistant depression.
00:22:11.759 --> 00:22:26.319
They compared 25 milligrams to 10 milligrams to 1 milligram, and the 1 milligram was thought to be pretty inactive of a synthetic pharmaceutical grade psilocybin formulation that they called COMP360.
00:22:27.039 --> 00:22:28.480
COMP360.
00:22:28.720 --> 00:22:29.920
Now this is the finding.
00:22:30.079 --> 00:22:42.240
At three weeks, the 25 milligram group showed a pretty significant mad risk reduction of 12.0 points compared to 5.4 on 1 milligram.
00:22:43.200 --> 00:22:46.000
And yeah, that's pretty significant.
00:22:46.079 --> 00:22:54.240
You can imagine 29.1% of patients in the 25 milligram group, in fact, achieved full remission.
00:22:54.799 --> 00:22:55.359
Wow.
00:22:55.599 --> 00:22:58.400
Now remember, these are not patients with depression.
00:22:58.640 --> 00:23:00.720
These are patients with TRD.
00:23:02.640 --> 00:23:11.279
Safety signal in this trial also deserves an honest mention because people did have an adverse event, headaches, nausea, dizziness.
00:23:12.400 --> 00:23:18.160
But no more frequently, especially after the first day was over.
00:23:18.960 --> 00:23:26.400
So it does talk about the need for careful clinical monitoring, regardless of treatment arm.
00:23:27.680 --> 00:23:30.559
Well, that phase two led to two more trials.
00:23:30.799 --> 00:23:35.519
They're phase three trials, they're called COMP005 and COMP006.
00:23:36.000 --> 00:23:40.960
And this year in 2026, both have reported their results.
00:23:41.200 --> 00:24:00.880
Well, essentially, I won't bore you with the details on them because we'll have other opportunities to talk about percentages, but I'm happy to tell you consistently, while the numbers may be different in this study or that study, psilocybin is effective, even in this tough-to-treat population.
00:24:01.599 --> 00:24:10.960
And that's really important that I make sure that the skeptics who might be listening, and there should be, and I hope there are quite a few who are in the listening audience.
00:24:11.519 --> 00:24:18.480
I think it's important that we appreciate that we have a good conversation.
00:24:18.720 --> 00:24:21.200
Are these huge effect sizes?
00:24:21.599 --> 00:24:21.920
No.
00:24:22.799 --> 00:24:25.839
Are they in a difficult to treat
population?
00:24:26.079 --> 00:24:26.720
Yes.
00:24:27.200 --> 00:24:33.279
Does that mean that this might have validity for certain patients and not for certain other patients?
00:24:33.599 --> 00:24:34.240
Yes.
00:24:34.799 --> 00:24:37.200
So please hold on to your skepticism.
00:24:37.359 --> 00:24:38.400
Don't let that go.
00:24:38.480 --> 00:24:54.079
But at the same time, please keep your mind open because the data is emerging from so many different angles that that psychedelics in fact can be quite helpful, not just for one day, but persistently.
00:24:55.039 --> 00:25:00.880
Now you might be thinking that fine, this is compared to itself or to placebo.
00:25:01.039 --> 00:25:06.480
What about when it's compared against a standard of care treatment like S Cetalopram?
00:25:06.960 --> 00:25:07.920
So guess what?
00:25:08.079 --> 00:25:09.039
There is such a study.
00:25:09.200 --> 00:25:11.200
It was done by Robin Carhardt Harris.
00:25:11.440 --> 00:25:15.839
It's a head-to-head study conducted at Imperial College in London.
00:25:16.000 --> 00:25:18.880
It got published in the New England Journal of Medicine.
00:25:19.119 --> 00:25:22.640
Easily the most prestigious journal in the world.
00:25:22.799 --> 00:25:30.960
It's not even a psychiatric journal, it's a medical journal of the first order, and they chose to publish it.
00:25:31.119 --> 00:25:33.359
You will see in a minute why they did.
00:25:33.599 --> 00:25:46.720
This was comparing two sessions of psilocybin therapy with six weeks of daily estalopram, Lexapro, in 59 patients with moderate to severe depression.
00:25:47.200 --> 00:25:53.119
Now they used a pre-specified primary outcome, that was the Quids SR16.
00:25:53.279 --> 00:25:58.000
The two treatments actually both did well, but did not differ significantly.
00:25:58.240 --> 00:25:59.599
So guess what the headline said?
00:25:59.759 --> 00:26:02.400
Psilocybin ties with SSRIs.
00:26:03.359 --> 00:26:10.079
But hold on, folks, those of us interested in positive psychiatry, we always dig a little bit deeper.
00:26:10.480 --> 00:26:16.000
So if you look at the secondary outcomes, a very different story emerged.
00:26:16.079 --> 00:26:19.359
And I'm so looking forward to telling you that story.
00:26:20.079 --> 00:26:30.079
Of the roughly 11 secondary scales measured, nearly all numerically favored psilocybin over S Cetalopram.
00:26:30.559 --> 00:26:49.599
Remission rates were twice twice as high with psilocybin, 57% versus 28% on Lexapro and on measures of well-being, specifically the Warwick-Edinburgh well-being scale, who that I really like, by the way, folks.
00:26:49.839 --> 00:26:55.920
Some of the time we're going to talk about that scale, as well as another scale called the flourishing scale.
00:27:01.519 --> 00:27:32.240
So there was a follow-up analysis published in e-Clinical Medicine in 2024 that compared out to six months and found that while both treatments produced comparable sustained reductions in depressive symptoms, patients in the psilocybin arm showed significantly greater sustained improvement in work and social functioning, in connectedness, when it was measured using a scale called the Watts Connectedness Scale.
00:27:32.480 --> 00:27:35.519
And also improvements in meaning in life.
00:27:36.400 --> 00:27:40.079
Yeah, even through the six months of follow-up.
00:27:40.640 --> 00:27:43.759
Now, let's talk about the flourishing scale specifically.
00:27:43.920 --> 00:27:54.240
The effect size at psilocybin at three months was 1.55 compared with Lexapro, Acetaliprim, which were 0.8.
00:27:55.359 --> 00:27:58.079
Oh my, that's almost 100% greater.
00:27:58.720 --> 00:28:13.039
So it does appear that psilocybin's effect on a very important component of positive psychiatry, which is flourishing, was huge, even though, even though, at least comparing quids SR, the data looked the same.
00:28:13.119 --> 00:28:20.960
But when it comes to remission, psilocybin was again nearly twice as effective as Lexapro.
00:28:22.480 --> 00:28:25.759
So yes, please do keep all these facts in mind.
00:28:26.960 --> 00:28:33.519
We now move over, if we can, to trauma, to PTSD.
00:28:34.400 --> 00:28:37.839
We really should talk about that because such a common problem.
00:28:38.000 --> 00:28:49.119
And we're going to talk about a very different molecule, MDMA, 3-4 methylene, dioxy, methamphetamine.
00:28:49.759 --> 00:28:51.279
Wow, it's a mouthful.
00:28:51.359 --> 00:28:53.519
How about we just take to MDMA?
00:28:54.000 --> 00:29:04.480
And now this works primarily by releasing serotonin, norepinephrine, and dopamine, and also by triggering oxytocin release.
00:29:05.119 --> 00:29:10.160
And this produces a state where the fear response is really diminished.
00:29:10.559 --> 00:29:17.759
There's increased interpersonal trust without the perceptual distortions of a classic psychedelic.
00:29:17.839 --> 00:29:21.680
So this is not a 5-HD2A agonist, okay?
00:29:22.480 --> 00:29:41.759
It is a very different molecule, and its pharmacologic profile makes it particularly suited to trauma processing, where the clinical bottleneck is often the patient's inability to approach traumatic material without becoming physiologically flooded and shutting down.
00:29:42.640 --> 00:29:43.920
Now, do we have data?
00:29:44.079 --> 00:29:45.599
Oh boy, we've got data.
00:29:45.680 --> 00:29:52.000
So the first phase three trial called MAPP1 was published in Nature Medicine.
00:29:52.240 --> 00:29:55.519
Folks, these are some heavy hitter journals.
00:29:56.240 --> 00:30:00.079
This was published in 2021 by Jennifer Mitchell and colleagues.
00:30:00.240 --> 00:30:10.240
It enrolled a lot of severely chronically ill patients with PTSD, 90 of them, average duration of illness, 14 years.
00:30:10.880 --> 00:30:14.960
They often had dissociation and depression and substance use history.
00:30:15.119 --> 00:30:15.920
Oh gosh.
00:30:16.160 --> 00:30:17.119
But get this.
00:30:18.240 --> 00:30:28.000
After three sessions of MDMA therapy, 67% of the MDMA group no longer met diagnostic criteria for PTSD.
00:30:28.319 --> 00:30:30.319
How did that compare to placebo?
00:30:30.480 --> 00:30:31.279
32%.
00:30:32.079 --> 00:30:35.279
It's more than 100% greater.
00:30:35.440 --> 00:30:36.720
The effect size?
00:30:37.039 --> 00:30:39.119
0.91.
00:30:40.240 --> 00:30:42.160
Well, you know, one trial's good.
00:30:42.400 --> 00:30:43.519
We need confirmation.
00:30:43.680 --> 00:30:44.720
So guess what?
00:30:44.880 --> 00:30:46.880
There is a confirmated trial.
00:30:47.039 --> 00:30:49.519
This one's called MAPP2.
00:30:50.000 --> 00:30:52.160
It also got published in Nature Medicine.
00:30:52.319 --> 00:30:53.519
What's going on here?
00:30:53.759 --> 00:30:58.799
But what's going on is the world is taking note, not just psychiatry.
00:30:59.039 --> 00:31:03.279
The world is taking note of emerging data in psychedelics.
00:31:03.359 --> 00:31:07.200
And this was a bigger study, 104 patients.
00:31:07.440 --> 00:31:17.359
And now the signal was 71.2% of patients no longer met PTSD criteria at the end of the study.
00:31:17.680 --> 00:31:18.319
Hmm.
00:31:19.039 --> 00:31:20.640
Pretty good stuff, right?
00:31:21.039 --> 00:31:32.319
Well, there are two more findings from these trials that deserve airtime right now because they speak directly to safety and the addiction liability question every clinician should ask.
00:31:32.559 --> 00:31:38.160
First, across both trials, there was no report of MDMA misuse or dependence.
00:31:38.400 --> 00:31:39.759
There wasn't any.
00:31:40.480 --> 00:31:51.680
Secondly, it was found that in the explorative finding, there was in fact reduction in hazardous alcohol use compared to placebo.
00:31:52.640 --> 00:32:08.160
That's really important that we do a reality check here because as you well know, in August 2024, the FDA actually turned down the new drug application for MDMA.
00:32:08.319 --> 00:32:10.000
They wanted more studies.
00:32:10.079 --> 00:32:15.359
They were concerned about trial design, functional and blinding, all appropriate worries.
00:32:16.079 --> 00:32:22.400
And you may have heard that Lycos, MDMA, is now in the hands of Lycos.
00:32:22.880 --> 00:32:29.279
They have resubmitted, resubmitted their package and have answered a lot of FDA's questions.
00:32:29.359 --> 00:32:41.359
So it's quite possible, quite possible that this data may lead to the FDA to approving it this particular time.
00:32:42.799 --> 00:32:48.319
Folks, let's talk about the third thing, which is addiction and recovery and positive psychiatry.
00:32:48.480 --> 00:32:50.079
Let's talk about that, shall we?
00:32:50.240 --> 00:32:55.359
Because positive psychiatry really emphasizes mastery and self-efficacy.
00:32:55.519 --> 00:32:58.960
And as you can imagine, addiction is a big enemy of it.
00:33:00.160 --> 00:33:04.480
Here's a name I think you and I both need to keep in mind.
00:33:04.799 --> 00:33:06.720
Michael Bogenschotz.
00:33:07.599 --> 00:33:15.759
And he and his colleagues at NYU, New York University, published in 2022 a double-blind study in JAMA.
00:33:16.160 --> 00:33:25.839
These were patients with alcohol use disorder, and they compared two sessions of high-dose psilocybin against an active placebo, and they used diaphenhydramine.
00:33:25.920 --> 00:33:28.960
Because, you know, diaphenhydramine makes you kind of feel different.
00:33:29.119 --> 00:33:31.359
So they're hoping to mask it.
00:33:31.920 --> 00:33:36.400
These folks also received 12 weeks of many psychotherapy.
00:33:36.720 --> 00:33:37.599
Get this.
00:33:37.920 --> 00:33:45.119
Over the 32 weeks in the follow-up period, the psilocybin group had a 83% reduction.
00:33:46.240 --> 00:33:55.680
83% reduction in percentage of heavy drinking days compared to 51% in the active placebo group.
00:33:56.319 --> 00:33:56.880
Wow.
00:33:57.279 --> 00:34:01.279
By eight months, 48% had completely stopped drinking.
00:34:02.079 --> 00:34:03.599
Placebo to 24%.
00:34:05.039 --> 00:34:05.519
Double.
00:34:06.319 --> 00:34:06.880
Double.
00:34:08.079 --> 00:34:14.239
Now why does this belong in a positive psychiatry episode rather than simply an addiction medicine episode?
00:34:14.400 --> 00:34:16.079
You might be asking, right?
00:34:16.719 --> 00:34:18.159
Well, here's why.
00:34:18.480 --> 00:34:46.079
Because the theoretical model researchers propose, and I completely buy onto it, is psilocybin might help not just depression, but alcohol use disorder, where the main challenge is these neurons, these default mode network functioning that leads to people getting stuck in rigid ways of thinking and rigid behaviors that follow.
00:34:46.400 --> 00:35:04.320
So I can completely see, and maybe you can too, that something that defrags or desynchronizes the default mode network and allows it to reconstitute could actually help not just addiction disorders or mood disorders, but both.
00:35:05.199 --> 00:35:08.960
Now there is one more section that I think we should touch upon.
00:35:09.280 --> 00:35:22.559
Can you think of one other group of patients where core concerns of meaning in life, death acceptance, purpose in life is more acute than this particular population?
00:35:22.960 --> 00:35:23.760
And guess what?
00:35:23.920 --> 00:35:47.199
This is what started the entire current day renaissance in psychedelics because Ronald Griffiths, Roland Griffiths and colleagues from Johns Hopkins published a study in Journal of Psychopharmacology in 2016 that could go down as one of the top five papers of the last century.
00:35:47.519 --> 00:36:04.480
And what they showed is that in 51 cancer patients facing a potentially life-threatening outcome, what they found is a substantial and sustained degree of improvement in depression and anxiety.
00:36:04.800 --> 00:36:19.360
But really importantly, they found that attitudes about life, about self, about relationships, about
mortality, about spirituality all had improved.
00:36:19.599 --> 00:36:33.760
In fact, four out of five patients in these studies endorsed that this was something that led to a moderate or greater increase in well-being or life satisfaction.
00:36:34.079 --> 00:36:35.440
Did you hear what I said?
00:36:35.599 --> 00:36:36.880
I hope you did.
00:36:37.280 --> 00:36:54.079
These are patients who are facing potentially the end of their life soon enough, yet after a high dose psilocybin treatment, four out of five are saying they had a moderate or greater increase in well-being or life satisfaction.
00:36:55.039 --> 00:37:02.880
Positive psychiatry really very much should be interested in psychedelics, scientifically and clinically.
00:37:03.679 --> 00:37:23.760
Now let's get to what I think is the single most important and most philosophically interesting finding in this entire literature, because it's the finding that most directly bridges the psychedelic pharmacology and positive psychiatry as a discipline, and that is the mystical experience.
00:37:24.400 --> 00:37:49.360
Nearly every trial we have discussed, cancer distress, TRD, regular depression, alcohol use disorder, PTSD, the magnitude of what we call mystical type experience, which can, by the way, be measured in a validated 30-item mystical experience questionnaire, it actually correlates with the magnitude of the clinical benefit.
00:37:49.840 --> 00:37:57.360
This was the first systematically shown by Griffiths and colleagues in the paper that I just talked about.
00:37:57.519 --> 00:38:00.159
But it's been replicated a huge number of times.
00:38:00.400 --> 00:38:07.039
For example, David Nutt and Carhart Harris showed this in 2018 with treatment-resistant patients.
00:38:07.280 --> 00:38:12.400
Garcia Romeo showed that in tobacco cessation research from Johns Hopkins.
00:38:12.480 --> 00:38:17.599
So this is not just one disorder, but a large group of disorders.
00:38:18.079 --> 00:38:23.440
Yes, mystical type reactions or mystical type experiences.
00:38:23.599 --> 00:38:27.760
Psychiatry typically has been very gun shy about discussing them.
00:38:28.000 --> 00:38:35.519
We often think of them as psychotic episodes or manic episodes, but that's not the case at all here.
00:38:35.840 --> 00:38:46.800
We literally will have to retool our vocabulary, folks, if we're going to become quality practitioners of the psychedelic medicine era.
00:38:48.320 --> 00:38:56.320
Now, here's the part that moves us from this interesting anecdote to measurable positive psychiatry outcome.
00:38:56.639 --> 00:39:04.400
There's a 2018 follow-up study from the same Johns Hopkins group that I shared with you that was published in the Journal of Psychopharmacology.
00:39:04.559 --> 00:39:08.800
But get this, they were followed for much longer periods of time.
00:39:08.960 --> 00:39:13.760
We're talking about one year, two years, three years, four years, five years.
00:39:14.480 --> 00:39:17.360
And very interesting.
00:39:17.920 --> 00:39:30.800
Not only did the depression and anxiety remain under control, things like gratitude, forgiveness, life meaning, and purpose, daily spiritual experience, religious faith, coping.
00:39:31.360 --> 00:39:39.440
Oh my gosh, those not only were elevated, they remained elevated on a sustained basis.
00:39:40.079 --> 00:39:53.599
So it doesn't matter if you are a psychopharmacologist who believes the whole brain is nothing but chemicals, or you are a devout psychotherapist who believes chemicals matter not.
00:39:54.239 --> 00:39:55.920
What matters is the mind.
00:39:56.079 --> 00:39:56.639
Guess what?
00:39:56.800 --> 00:39:58.159
You have a home.
00:39:58.400 --> 00:40:11.920
You have a home, a collective home in the psychedelic world, because the psychedelic world really does combine psychopharmacology with even things like mystical experiences.
00:40:13.360 --> 00:40:29.360
I found that extraordinarily interesting, and I wanted to make sure that I shared it with you, because in addition to everything else, psilocybin occasioned mystical experience produce a sustained increase in the personality trait of openness.
00:40:30.320 --> 00:40:35.519
As you know, this trait of openness is one of the big five personality dimensions.
00:40:35.760 --> 00:40:41.280
And if you improve that, oh Lord, it helps improve so much.
00:40:41.599 --> 00:40:49.760
It reduces what psychiatric illnesses often do, which is to create a locked-in state for the patient.
00:40:50.320 --> 00:41:00.159
I should add something that's very important, that the quality of the therapeutic alliance between the patient and their facilitator significantly matters.
00:41:00.400 --> 00:41:03.920
This is not as simple as drug-in, outcome out.
00:41:04.079 --> 00:41:05.599
It's not that simple.
00:41:06.000 --> 00:41:11.519
This relationship genuinely does affect the quality of ultimate outcomes.
00:41:11.679 --> 00:41:33.440
So those of us who are interested in psychedelics and in positive psychiatry will not only want to know our medications inside out, the psychedelic medications inside out, but we will have to develop a skill set and sharpen our skill set at being expert facilitators and perhaps even psychotherapists.
00:41:33.760 --> 00:41:44.480
As we get close to the end of our time today, I think we need to translate all of this into something we can actually use in clinic, right?
00:41:44.880 --> 00:41:51.920
Because a purely academic recap doesn't do justice to why you and I here together on this podcast.
00:41:52.239 --> 00:41:56.800
First, screening still comes before enthusiasm.
00:41:57.039 --> 00:42:01.360
Every trial we discussed today excluded certain kinds of patients.
00:42:02.000 --> 00:42:08.800
Like if you had a family history of psychosis or even a whiff of potential bipolar disorder.
00:42:09.039 --> 00:42:11.760
Well, in our hands, that won't be the case.
00:42:12.000 --> 00:42:18.400
So we will have to appreciate while these
trials are very important, there might be shortcomings in it.
00:42:19.199 --> 00:42:30.639
But it's also really important we appreciate that the data doesn't just show improvement in depression or anxiety or drinking or depression and anxiety after a life-threatening illness.
00:42:30.880 --> 00:42:36.559
It in fact shows improvement in well-being, in flourishing, in meaning in life.
00:42:36.719 --> 00:42:45.360
These are core, core benefits and assets that we talk about in positive psychiatry.
00:42:45.920 --> 00:42:54.719
It does appear, it does appear, this question, psychedelics and positive psychiatry, are they a marriage made in heaven?
00:42:55.039 --> 00:42:56.960
Very likely they are.
00:42:57.920 --> 00:43:06.159
So positive psychiatry asks us to measure and cultivate meaning and connectedness and resilience and flourishing.
00:43:06.639 --> 00:43:13.519
And yes, majority of the data that I've shown you, in fact, demonstrates that.
00:43:13.679 --> 00:43:16.320
Now, this is genuinely new in our field.
00:43:16.559 --> 00:43:19.679
No, it does not mean every patient is a candidate.
00:43:19.920 --> 00:43:23.760
It does not mean all the regulatory and access questions are solved.
00:43:23.920 --> 00:43:25.039
Far from it.
00:43:25.440 --> 00:43:33.119
And I don't mean to suggest that we should abandon clinical and scientific rigor for enthusiasm.
00:43:33.599 --> 00:43:43.920
But I think what I'm asking for, what I'm suggesting is we should hold all those feelings in our mind at the same time.
00:43:44.159 --> 00:43:48.159
Rigor, scientific curiosity, and enthusiasm.
00:43:48.480 --> 00:43:51.519
There's a place in our mind for all of that.
00:43:51.840 --> 00:43:56.320
Because there's one thing about positive psychiatry, it is not based in fluff.
00:43:56.800 --> 00:44:00.400
It's a science of measuring and building human flourishing.
00:44:00.639 --> 00:44:12.400
And those of us who practice psychiatry, we definitely want to be even better at our game than simply the treatment of symptoms.
00:44:12.639 --> 00:44:28.400
That's why I am proposing that we should very carefully think that psychedelics may in fact marry positive psychiatry in a manner that really could help a very large number of patients.
00:44:28.639 --> 00:44:40.400
There'll be so much more to discuss, folks, over the upcoming months because a large number of data sets are going to be appearing soon that will be discussing exactly this overlap.
00:44:41.119 --> 00:44:45.840
But at the moment, it does seem there is indeed a very good marriage.
00:44:51.599 --> 00:44:58.000
Folks and this is Rakesh Jan, thank you so much for spending about 45 minutes with me.
00:44:58.159 --> 00:45:10.880
I hope I offered you a combination of good science, good understanding, but also good data, so that you can make up your own mind for yourself.
00:45:11.519 --> 00:45:16.960
Thanks again, and I'll see you next time on another episode of How to Tyson Python.
00:45:19.280 --> 00:45:20.239
Goodbye.